Featured Research

from universities, journals, and other organizations

Researchers reduce breast cancer spread by blocking tissue scarring

Date:
January 24, 2013
Source:
University of Copenhagen
Summary:
What to fear most if faced by a cancer diagnosis is the spread of the cancer to other parts of the body. Metastasis accounts for over 90 percent of cancer patient deaths. Researchers have shown that the enzyme Lysyl Oxidase (LOX) can create a "scarred" microenvironment that enhances cancer spreading. By blocking activity of the LOX enzyme, the researchers succeeded in significantly decreasing metastasis in a model of breast cancer.

Metastasis of breast cancer cells in the lung.
Credit: Image courtesy of University of Copenhagen

What to fear most if faced by a cancer diagnosis is the spread of the cancer to other parts of the body. This process called metastasis accounts for over 90% of cancer patient deaths and therefore is a strong focus for cancer researchers. Researchers at BRIC, University of Copenhagen have shown that the enzyme Lysyl Oxidase (LOX) can create a "scarred" microenvironment that enhances cancer spreading. By blocking activity of the LOX enzyme, the researchers succeeded in significantly decreasing metastasis in a model of breast cancer.

Related Articles


'When we inhibit the activity of LOX in our cancer models, we show a dramatic reduction in metastasis. This suggests that therapeutic targeting of LOX can keep the tumour microenvironment "healthy" and thereby decrease metastasis, says Associate Professor Janine Erler from BRIC, who has headed the research.

LOX -- A link between tissue scarring and metastasis

In humans, LOX is an enzyme that is produced in response to tissue injury or chronic inflammation in our organs. It reacts to damage signals and "glues" collagen molecules together to form the scar-like structure. The result can be a fibrotic environment. The new findings from Janine Erler's research group show that persistent injury to lung and liver results in a fibrotic microenvironment that supports the growth of new tumours, and thereby enhances metastasis of breast cancer cells to these organs. Blocking LOX prevents the formation of this fibrotic microenvironment, thereby preventing enhanced metastasis to these organs.

'It is well-known that signals from fibrotic tissues can enhance tumour progression and metastasis, but the underlying mechanisms have remained unclear -- Our new results provide insight into the link between fibrosis and cancer progression. Such a biological understanding is crucial if we are to develop effective therapies preventing tumour metastasis, says PostDoc Thomas Cox from Janine Erler's laboratory, who undertook the experimental investigation.

Development of new anti-fibrotic therapies

Currently, LOX-targeting therapies are under development for use in the clinic against cancer, as it has been known for some while that metastatic tumours express increased amounts of LOX. Yet, the new results from Janine Erler's group are the first to show that LOX promotes distant metastasis through structural changes in the organ microenvironments in response to persistent injury. The next step for the researchers is to dig deeper into the mechanisms underlying the relationship between fibrosis and cancer metastasis, and also to test their findings in other cancer models such as gastric and colon cancer.

'Further, our study indicates that LOX-targeting therapy can be relevant not only for cancer patients, but also to prevent fibrosis in patients with chronic inflammation or patients who has been exposed to persistent organ injury. This opens up for an even wider applicability of our biological findings, which strongly motivates the basic research in my laboratory, says Janine Erler.

The results have just been published in the international journal Cancer Research. The work was initiated at the Institute of Cancer Research UK and completed at BRIC. The work has been supported by research grants from the Cancer Research UK and the Novo Nordisk Foundation.


Story Source:

The above story is based on materials provided by University of Copenhagen. Note: Materials may be edited for content and length.


Journal Reference:

  1. T. R. Cox, D. Bird, A.-M. Baker, H. E. Barker, M. W.-Y. Ho, G. Lang, J. T. Erler. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Research, 2013; DOI: 10.1158/0008-5472.CAN-12-2233

Cite This Page:

University of Copenhagen. "Researchers reduce breast cancer spread by blocking tissue scarring." ScienceDaily. ScienceDaily, 24 January 2013. <www.sciencedaily.com/releases/2013/01/130124123445.htm>.
University of Copenhagen. (2013, January 24). Researchers reduce breast cancer spread by blocking tissue scarring. ScienceDaily. Retrieved March 5, 2015 from www.sciencedaily.com/releases/2013/01/130124123445.htm
University of Copenhagen. "Researchers reduce breast cancer spread by blocking tissue scarring." ScienceDaily. www.sciencedaily.com/releases/2013/01/130124123445.htm (accessed March 5, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, March 5, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Adults Only Get The Flu Twice A Decade, Researchers Say

Adults Only Get The Flu Twice A Decade, Researchers Say

Newsy (Mar. 4, 2015) Researchers found adults only get the flu about once every five years. Scientists analyzed how a person&apos;s immunity builds up over time as well. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins